Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06144164

A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer

A Prospective Cohort Study of Patients Undergoing ALND for Treatment of Breast Cancer: The Efficacy of a Comprehensive Prevention Program in Decreasing the Incidence of Lymphedema and Improving Quality of Life

Status
Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
285 (estimated)
Sponsor
Memorial Sloan Kettering Cancer Center · Academic / Other
Sex
Female
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.

Conditions

Interventions

TypeNameDescription
PROCEDUREImmediate Lymphatic ReconstructionImmediate Lymphatic Reconstruction will happen at the time of Axillary Lymph Node Dissection
DIAGNOSTIC_TESTVolumetric arm measurementsVolumetric arm measurements will occur at each in-person postoperative visit time points.
OTHERLymphatic massageParticipants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
OTHERRange of motion exercisesParticipants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
OTHERCompression garment useParticipants will use compression garments 24 to 48 h after surgery and will continue daily use for at least 8 h a day for 3 months or until 3 months after any adjuvant treatments are completed

Timeline

Start date
2023-11-16
Primary completion
2030-03-16
Completion
2030-03-16
First posted
2023-11-22
Last updated
2025-11-10

Locations

7 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT06144164. Inclusion in this directory is not an endorsement.